However, it has been observed that sustainability and durability of CAIX inhibition, even in combination with chemotherapy agents, is limited by the occurrence of adaptive resistance, resulting in tumour recurrence (Lou et al., 2011; Lock et al., 2013; Boyd et al., 2017; Chafe et al., 2019; McDonald et al., 2019). The gene discussed is CA9; the disease is neoplasm.